SAN FRANCISCO—EcoR1 Capital, LLC, a significant shareholder in Tango Therapeutics, Inc. (NASDAQ:TNGX), recently sold a substantial portion of its holdings in the pharmaceutical company. The transactions, which took place on November 6 and 7, involved the sale of 2,697,000 shares of common stock, generating approximately $8.4 million.
The sales were executed at prices ranging from $2.9171 to $3.2914 per share. Following these transactions, EcoR1 Capital retains ownership of 10,630,736 shares in Tango Therapeutics.
EcoR1 Capital, managed by Oleg Nodelman, is an investment adviser and general partner of private funds, including the EcoR1 Capital Fund Qualified, L.P., which directly holds these securities for the benefit of its investors.
In other recent news, Tango Therapeutics has made significant strides in its drug development pipeline. The company has advanced its cancer drug candidate TNG462 into full development following positive early trial results, showing promise in treating multiple tumor types, including non-small cell lung cancer and pancreatic cancer. In contrast, Tango Therapeutics has decided to halt enrollment for TNG908 to focus resources on the development of TNG462 and TNG456, a next-generation treatment for glioblastoma and other solid tumors.
The company’s decision comes after TNG462 demonstrated effectiveness and tolerability, with patients maintaining treatment for a median duration of 24 weeks. In collaboration with Revolution Medicines, Tango Therapeutics will evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors to treat MTAP-deleted cancers. Analyst firms including H.C. Wainwright, Leerink Partners, and Piper Sandler have maintained their Buy, Outperform, and Overweight ratings respectively on Tango Therapeutics, citing recent data from clinical trials and competitor drugs.
Despite halting the development of TNG348 due to observed liver function abnormalities in trial participants, Tango Therapeutics’ cash runway is projected to last until 2027. This financial stability enables the company to continue exploring other therapeutic opportunities, particularly within the PRMT5 program. The company is also preparing for year-end clinical updates for its PRMT5 inhibitors, TNG908 and TNG462. Analysts anticipate significant data updates for both TNG908 and TNG462 programs in the second half of 2024, which are expected to be pivotal for the company’s progress and investor confidence.
InvestingPro Insights
The recent stock sale by EcoR1 Capital comes at a time when Tango Therapeutics (NASDAQ:TNGX) is facing significant market challenges. According to InvestingPro data, the company’s stock has experienced a dramatic decline, with a 42.72% drop in the past week and a 65.29% fall over the last three months. This sharp downturn aligns with an InvestingPro Tip indicating that the stock’s RSI suggests it is in oversold territory.
Despite these market pressures, Tango Therapeutics maintains a strong liquidity position. An InvestingPro Tip highlights that the company holds more cash than debt on its balance sheet, which could provide some financial flexibility as it navigates current headwinds. This cash position is particularly crucial given another InvestingPro Tip noting that the company is quickly burning through cash.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Tango Therapeutics. These insights could prove valuable in understanding the company’s financial health and future prospects amidst its current market volatility.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
